Your browser doesn't support this page

This website uses the latest technology, and it looks like your browser doesn't support some of the latest features.

You'll probably be able to see the content with the browser you have, but we encourage you to choose a browser with better support for the future of the web. These support all the features used (and they're free too):

Google Chrome Mozilla Firefox Safari Dismiss
Håvard E. Greger Danielsen

Contact information

Please contact Håvard E. Greger Danielsen for more information


- Improved Risk Stratification of Prostate Cancer Patients

Many have studied and reported a large variety of observed changes related to carcinogenesis and diagnosis and prognosis of cancer. Many have statistically demonstrated how a number of these changes are interrelated. A typical finding for a prostate cancer patient with a poor outcome would initially be a high Gleason score (8-10), an elevated PSA level (>20 ng/ml), and a large bilateral tumor (T2c or higher). However, this would only apply to around 50% of these cases, but not many more. Furthermore, genomic analysis of a prostate cancer cohort would typically show aneuploidy, activated MYC, deactivated P53, presence of the fusion gene TMPRSS2-ERG, increased chromatin entropy and so on, but most patients would only display some of these changes and very seldom all. There is no question that all of these factors in one way or another are related to prognosis, but it is unclear how they relate to each other and it is unclear to what extent and how they influence the outcome of a given patient. We postulate that conflicting results often are due to averaging effects, and that by looking at the different parameters on a cell-by-cell basis, it will be easier to identify the characteristics of cells with metastatic ability.

Our aim with this project is to improve risk stratification of prostate cancer patients and provide novel tools for identification of biomarkers on a cell-by-cell basis.

Related articles

Chief Editor: Prof. Håvard E. Danielsen
Copyright Oslo University Hospital. Visiting address: The Norwegian Radium Hospital, Ullernchausséen 64, Oslo. Tel: 22 78 23 20